BOT - Anything but charting, page-3474

A post in another thread, that pointed out the miniscule income that SB (Ecclock) is making in Japan ($11m), got me thinking that perhaps the market in general is so underwhelmed by BOT's SB acquisition, because the potential price differential for the product is simply not understood? In Japan, SB sells for about $50 a script. In the US, BOT intend to sell it for around $540 a script (that's freedom for ya!). That's 10 x the income - so BOT don't even need to sell as much SB to the US market, as is already sold to the Japanese market, to earn more than $100m a year off the bat.

Yes there is the risk that FDA won't approve (miniscule), and maybe the risk that Insurer's won't play the game with BOT and allow them to sell SB for that much (although with an existing >$1b market for hyperhidrosis and 16 million potential clients, I'm not sure that's credible), but I'm at a loss to understand why the market hasn't embraced this acquisition. But I'm a novice, so would appreciate any info/suggestions.